OCT1 Polyspecificity—Friend or Foe?

Marleen J. Meyer* and Mladen V. Tzvetkov

Institute of Pharmacology, Center of Drug Absorption and Transport (C_DAT), University Medicine Greifswald, Greifswald, Germany

Keywords: OCT1, SLC22A1, polyspecificity, structure-to-function relationship, ligand-transporter interaction, species differences, genetic variants

INTRODUCTION

Polyspecificity is one of the most characteristic features of organic cation transporter OCT1 (SLC22A1). Already upon the initial cloning it was recognized that the OCT1-mediated uptake could be inhibited by a variety of substances with different chemical structures (Gründemann et al., 1994). Following the initially identified substrate TEA⁺, the organic cations MPP⁺ and ASP⁺ and endogenous compounds such as dopamine and histamine were described as substrates (Gründemann et al., 1994; Busch et al., 1996a; Busch et al., 1996b; Mehrens et al., 2000), showing that not only aliphatic, but also aromatic cations with variable structures could be OCT1 substrates. Currently, more than 150 organic cationic compounds with highly variable chemical structures, including also commonly used drugs like metformin, morphine, sumatriptan, fenoterol, and lamotrigine have been reported to be substrates of the organic cation transporter OCT1 (Wang et al., 2002; Dickens et al., 2012; Tzvetkov et al., 2013; Matthaei et al., 2016; Shen et al., 2016; Tzvetkov et al., 2018; Haberkorn et al., 2021).

However, polyspecificity does not mean unspecific. We recently reported that small differences in the chemical structures of morphinan opioids lead to substantial differences in the inhibitory potency or even to the inability to interact with human OCT1 (Meyer et al., 2019).

Twenty-seven years after OCT1 discovery, the mechanisms conferring its polyspecificity are still poorly understood. Our current knowledge about the mechanisms of OCT1-mediated transport is predominantly based on mutagenesis experiments. Several amino acids have been suggested to be of key importance for substrate binding and/or translocation (Gorboulev et al., 1999; Gorboulev et al., 2005; Popp et al., 2005; Sturm et al., 2007; Volk et al., 2009). The most prominent thereof is Asp475 in transmembrane helix 11, which is generally accepted to play a key role by interacting with the positive charge of the substrate. However, OCT1 is thought to have multiple binding sites that may overlap between substrates (Gorboulev et al., 1999; Popp et al., 2005; Volk et al., 2009; Chen et al., 2017; Boxberger et al., 2018), but there is no crystal structure available, neither for OCT1, nor for any of the closely related proteins of the SLC22A family. The homology models used instead are based on distantly related transporters that share maximally 19.5% identity with human OCT1 (Koepsell, 2020). Therefore, the exact binding sites of the different OCT1 substrates remain unclear.

OCT1 POLYSPECIFICITY AS A FOE

In many regards, the polyspecificity of OCT1 represents a disadvantage. It complicates the experimental analysis and the interpretation of the obtained results.

Firstly, OCT1 polyspecificity is a hurdle when studying the mechanisms of transport. Most of our current knowledge about OCT1 structure-to-function relationships has been obtained using MPP⁺ or TEA⁺ as substrates (Gorboulev et al., 1999; Gorboulev et al., 2005; Popp et al., 2005; Volk et al., 2009; Keller et al., 2019). Already for these two substrates, substrate-specific differences in the role of key amino acids were reported. While mutation of Arg440Lys affected the affinity for TEA⁺ but not
for MPP⁺, mutation of Phe160Ala affected the affinity for MPP⁺ but not for TEA⁺ (Gorboulev et al., 2018). This may not be surprising, considering the structural differences between the two substrates. On the contrary, different ligands can be expected to interact with different amino acids of the transporter. Thus, despite their name, the so-called model substrates may be of only limited use for predictions of substrate-transporter interactions for clinically relevant ligands. Therefore, at least until we better understand the structural mechanisms of OCT1 polyspecificity, structure-to-function relationships have to be established for each substrate separately. As a practical consequence, *in vitro* data on inhibitory potencies using OCT1 model substrates may be of only limited predictive value for drug-drug-interactions (DDIs) with the actual victim drug (Koopsell, 2015, 2020; Hermann, 2021).

Secondly, in addition to the difficulties of transferring structure-to-function findings between substrates, polyspecificity aggravates the transfer of findings between species. Most of the available structure-to-function data have been obtained studying rat Oct1 (Gorboulev et al., 1999; Gorboulev et al., 2005; Popp et al., 2005; Sturm et al., 2007; Volk et al., 2009). However, human and rat OCT1 differ in 120 amino acids and each of them may potentially cause differences in OCT1 function. There is not much data directly comparing rat and human OCT1, but the affinity and the capacity of metformin and thiamine transport have been shown to differ substantially between mouse and human OCT1 (Chen et al., 2014; Meyer et al., 2020). Based on these differences, up to 11-fold higher maximal metformin concentrations may be expected in mouse than in human liver and hepatic effects of metformin in humans may be overestimated (Meyer et al., 2020). This may explain why loss of OCT1 activity in humans does not affect metformin efficacy (Zhou et al., 2009; Dujic et al., 2017) in contrast to strong effects observed in OCT1 knock-out mice (Wang et al., 2002; Wang et al., 2003).

More importantly, due to OCT1 polyspecificity, the species differences are also substrate-specific. While OCT1 inhibition results in strong differences in the uptake of ondansetron and tropisetron between mouse and human hepatocytes, no differences were observed for sumatriptan and fenoterol (Morse et al., 2020). Therefore, next to the known differences in OCT1 organ expression between the species (Gründemann et al., 1994; Schweifer and Barlow, 1996; Gorboulev et al., 1997; Green et al., 1999), differences in transport activity have to be kept in mind when interpreting existing data from animal models and cannot be generalized among the substrates.

Thirdly, polyspecificity leads to substrate-specific effects of genetic variants in OCT1. OCT1 is genetically highly variable and common genetic variants lead to a reduction or to a loss of OCT1 function (Kerb et al., 2002; Shu et al., 2003; Seitz et al., 2015). Some of these variants have substrate-specific effects. The most common OCT1 variant in Europeans and White Americans (Seitz et al., 2015), the deletion of Met420 (OCT1*2), reduces the uptake of metformin, morphine, tropisetron, and O-desmethyllumadomol (O-DSMT) by more than 75% (Shu et al., 2007; Tzvetkov et al., 2011; Tzvetkov et al., 2012; Tzvetkov et al., 2013), but shows normal or only slightly reduced uptake of sumatriptan, cycloguanil, and debrisoquine (Saadatmand et al., 2012; Matthaei et al., 2016; Matthaei et al., 2019). Therefore, homozygous carriers of OCT1*2 have to be regarded as complete loss-of-function phenotypes (so-called poor OCT1 transporters) when tramadol is administrated and as fully active (extensive OCT1 transporters) when sumatriptan is administrated. Hence, individual OCT1 activity scores have to be substrate-specific and cannot be generalized. This complicates the use of OCT1 pharmacogenetics in the clinical routine and requires clinical studies for each substrate.

Finally, the polyspecificity of OCT1 questions the idea of one “ultimate” pharmacophore valid for OCT1 ligands. Indeed, the published ligand-based pharmacophore models of OCT1 differ in the number, type, and distance of their features. While the models of Bednarczyk et al. (2003), Moaddel et al. (Moaddel et al., 2005; Moaddel et al., 2007) and from our group (Meyer et al., 2019) show some resemblance, the model by Nies et al. (2011) shows more pronounced differences, the most striking being the absence of a positively ionizable site. This is not surprising and may simply reflect the coexistence of different binding sites in OCT1. Therefore, before we understand which ligands bind to which binding sites, it will be difficult to correctly identify chemical features necessary for interaction with OCT1.

**OCT1 POLYSPECIFICITY AS A FRIEND**

When utilized properly, the polyspecificity of OCT1 can also be an ally in understanding the transport mechanisms of OCT1. Many of the disadvantages listed above can be turned into experimental tools to study polyspecificity.

Firstly, the *in vitro* prediction of DDIs should be performed with more than one (victim) substrate, comparing the inhibitory potencies as has been done already for OCT2 (Hacker et al., 2015; Sandovan et al., 2018) and partially for OCT1 (Ahlin et al., 2011). This strategy has two advantages. First, using the victim drug of interest and not a model substrate enables more precisely predicting DDIs in humans. Second, and more interesting, it enables analyzing the interactions in the context of the specific substrate used. This may help identifying clusters of ligands (substrates and inhibitors) that potentially share binding positions in OCT1. In the long term, this may help to stratify ligands into groups according to similar binding properties and to generate subgroup-specific pharmacophores.

Secondly, comparing the interaction with OCT1, ligands with closely related structures may help to identify moieties that are important for the interaction. Systematic comparison of the OCT1 inhibitory potency of structurally similar morphinan opioids revealed that only minor structural changes, involving the ether linkage between C4-C5 of the morphinan ring, strongly increased the inhibitory potency for OCT1 (Meyer et al., 2019). Such systematic “ligand structure walking” may prove to be very useful to better understand the role of the ligand structure in the OCT1 transport mechanism.

All examples of experiments listed above are possible today due to technical advancement of the analytical methods. In
contrast to the first decades of studying OCT1 where scientists were limited by the availability of radioactive OCT1 substrates, today we can use techniques such as LC-MS/MS to quantify practically any substrate of interest. The sensitivity is still not as high as in radioactive detection, but the quantification of the intracellularly accumulated substrate is highly specific. This enabled first high-throughput screens for OCT1 substrates (Hendrickx et al., 2013) and also detailed analyses of substrates with only slightly different chemical structures (Meyer et al., 2019) up to stereoselective effects of the uptake (Jensen et al., 2020).

Approaching polyspecificity from the transporter side, the species-specific differences in OCT1 transport can be used as a tool to identify domains or even single amino acids responsible for the substrate-specific effects on transport. In a proof-of-principle study we used human-mouse chimeric constructs to localize the cause for the higher affinity of mouse OCT1 for thiamine and metformin to transmembrane helices 2 and 3 (Meyer et al., 2020). For metformin, we were even able to fine-map the causal difference to the difference between Leu155 in human and Val156 in mouse OCT1. This strategy is extendable to all substrates showing species-specific differences in uptake. Furthermore, similar to the ortholog comparison, also paralogs with different substrate preferences may be compared, as has successfully been done for rat Oct1 and Oct2 (Goroubelev et al., 2005).

Similarly, substrate-specific effects of some OCT1 genetic variants may help to reveal details in the mechanism of OCT1 transport. By comparing the effects of genetic variants with substrate-specific effects on different substrates, we can identify substrates that are similarly affected and thus may share similar binding sites in the transporter. To illustrate this, we used previously published data about the effects of the substrate-specific OCT1 genetic variants OCT1*2, *7, *10, *11, and *13 from our group (Figures 1B,C (Tzvetkov et al., 2012; Tzvetkov et al., 2013; Seitz et al., 2015; Matthaei et al., 2016; Meyer et al., 2017)). The effects on the uptake of metformin and monocrotaline, but also of morphine and ranitidine correlated very well (r of 0.995 and 0.98, respectively; Figure 1), suggesting at least two groups of structurally divergent substrates that may share similar binding sites in OCT1. This strategy could be used to cluster ligands into subgroups based on the impact of the substrate-specific OCT1 genetic variants. Such subgroups could be used to develop subgroup-specific pharmacophores (similar to those suggested above for analyses of substrate-specific DDIs) and to identify subgroup-specific model substrates that will facilitate the handling of OCT1 pharmacogenetics in a clinical setting.

SUMMARY

The polyspecificity of OCT1 sets many hurdles for understanding the transport mechanisms of OCT1 and for the translation of our knowledge about OCT1 into clinical practice. However, polyspecificity may be used also as a tool, especially to reveal the mechanisms of OCT1 transport, which is an essential step for deepening our understanding of the physiological functions and potential pharmacological implications of this transporter.

AUTHOR CONTRIBUTIONS

MM and MT analyzed the data and wrote the manuscript.

ACKNOWLEDGMENTS

Parts of this article are based on data and views that have previously been stated in the PhD thesis of MM (Meyer, 2020).
REFERENCES

Ahlin, G., Chen, L., Lazorova, L., Chen, Y., Ianculescu, A. G., Davis, R. L., et al. (2011). Genotype-dependent Effects of Inhibitors of the Organic Cation Transporter, OCT1: Predictions of Metformin Interactions. Pharmacogenomics J. 11, 400–411. doi:10.1038/tpj.2010.54

Bednarczyk, D., Ekins, S., Wikel, J. H., and Wright, S. H. (2003). Inhibition of Cellular Uptake Mediated by Human Organic Cation Transporters 1 and 2. J. Med. Chem. 56, 7232–7242. doi:10.1021/jm030096v

Herrmann, K. (2021). Update on Drug-Drug Interaction at Organic Cation Transporters: Mechanisms, Clinical Impact, And Proposal For Advanced In Vitro Testing. In: Expert Opinion on Drug Metabolism Toxicology. doi:10.1080/17425525.2021.1915284

Jensen, O., Raffel, M., Tzetvetsk, M. V., and Brockmöller, J. (2020). Stereoselective Cell Uptake of Adrenergic Agonists and Antagonists by Organic Cation Transporters. Biochem. Pharmacol. 171, 113731. doi:10.1016/j.bcp.2019.113731

Keller, T., Gorboulev, V., Mueller, T. D., Dötsch, V., Bernhard, F., and Koepsell, H. (2019). Rat Organic Cation Transporter 1 Contains Three Binding Sites for Substrate 1-Methyl-4-Phenylpyridinium Per Monomer. Mol. Pharmacol. 95, 169–182. doi:10.1124/mpha.2018.113498

Koepsell, H. (2020). Organic Cation Transporters in Health and Disease. Pharmacol. Rev. 72, 253–319. doi:10.1124/pr.118.015578

Koepsell, H. (2015). Role of Organic Cation Transporters in Drug-Drug Interaction. Exp. Opin. Drug Metab. Toxicol. 11, 1619–1633. doi:10.1517/17425525.2015.1069274

Meyer, M. J. (2020). Differences on the Function of Organic Cation Transporter OCT1 Is Increased by Protein Kinase C-dependent Phosphorylation. JASN 11, 1216–1224. doi:10.1681/asn.1171216

Meyer, M. J. (2020). Effects of Ligand Structure, Amino Acid Substitutions, and Species Differences on the Function of Organic Cation Transporter OCT1: Utilizing Polyspecificity for Understanding Structure-Function Relationships. Doctoral Thesis. Greifswald, Germany: University of Greifswald, Institute of Pharmacology.

Meyers, M. J., Neumann, V. E., Friesacher, H. R., Zdrazil, B., Brockmöller, J., and Tzetvetsk, M. V. (2019). Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. J. Med. Chem. 62, 9899–9905. doi:10.1021/acs.jmedchem.9b01301

Meyers, M. J., Seitz, T., Brockmöller, J., and Tzetvetsk, M. V. (2017). Effects of Genetic Polymorphisms on the OCT1 and OCT2-Mediated Uptake of Ranitidine. PLoS ONE 12, e0189521. doi:10.1371/journal.pone.0189521

Meyers, M. J., Tuerkova, A., Römer, S., Wenzel, C., Seitz, T., Gaedcke, J., et al. (2020). Differences in Metformin and Thiamine Uptake between Human and Mouse Organic Cation Transporter 1: Structural Determinants and Potential Consequences for Intrahepatic Concentrations. Drug Metab. Dispos 48, 1380–1392. doi:10.1124/dmd.120.001570

Moaddel, R., Patel, S., Jozwiak, K., Yamaguchi, R., Ho, P. C., and Wainer, I. W. (2005). Enantioselective Binding to the Human Organic Cation Transporter-1 (hOCT1) Determined Using an Immobilized hOCT1 Liquid Chromatographic Stationary Phase. Chirality 17, 501–506. doi:10.1002/chir.20195

Moaddel, R., Ravichandran, S., Bghj, F., Yamaguchi, R., and Wainer, I. W. (2007). Pharmacophore Modelling of Stereoselective Binding to the Human Organic Cation Transporter (hOCT1). Br. J. Pharmacol. 151, 1305–1314. doi:10.1038/bjp.0703s41

Morse, B. L., Kolur, A., Hudson, L. R., Hogan, A. T., Chen, L. H., Brackman, R. M., et al. (2020). Pharmacokinetics of Organic Cation Transporter 1 (OCT1) in Oct/1 Knockout Mice and Species Difference in Hepatic OCT1-Mediated Uptake. Drug Metab. Dispos 48, 93–105. doi:10.1124/dmd.119.108781

Nies, A. T., Hofmann, U., Resch, C., Schaeffer, E., Rius, M., and Schwab, M. (2011). Proton Pump Inhibitors Inhibit Metformin Uptake by Organic Cation Transporters (OCTs). PLoS ONE 6, e22163. doi:10.1371/journal.pone.0022163

Popp, C., Gorboulev, V., Müller, T. D., Gorbunov, D., Shatskaya, N., and Koepsell, H. (2005). Amino Acids Critical for Substrate Affinity of Rat Organic Cation Transporter 1 (OCT1) Polyspeci...
Transporter 1 Line the Substrate Binding Region in a Model Derived from the Tertiary Structure of Lactose Permease. Mol. Pharmacol. 67, 1600–1611. doi:10.1124/mol.104.008839

Saadatmand, A. R., Tadjerpisheh, S., Brockmöller, J., and Tzvetkov, M. V. (2012). The Prototypic Pharmacogenetic Drug Dpliedase is a Substrate of the Genetically Polymorphic Organic Cation Transporter OCT1. Biochem. Pharmacol. 83, 1427–1434. doi:10.1016/j.bpc.2012.01.032

Sandoval, P. J., Zorn, K. M., Clark, A. M., Ekins, S., and Wright, S. H. (2018). Assessment of Substrate-dependent Ligand Interactions at the Organic Cation Transporter OCT2 Using Six Model Substrates. Mol. Pharmacol. 94, 1057–1068. doi:10.1124/mol.117.111443

Schweifer, N., and Barlow, D. P. (1996). The Lsl Gene Mops to Mouse Chromosome 17 and Codes for a Protein that Is Homologous to Glucose and Polyspecific Transmembrane Transporters. Mamm. Genome 7, 735–740. doi:10.1007/s003359900223

Seitz, T., Stalmann, R., Dalila, N., Chen, J., Poir, S., Dos Santos Pereira, J. N., et al. (2015). Global Genetic Analyses Reveal strong Inter-ethnic Variability in the Loss of Activity of the Organic Cation Transporter OCT1. Genome Med. 7, 56. doi:10.1186/s13073-015-0172-0

Shen, C.-H., Zhang, X.-X., Lu, R.-Y., Jin, B., Wang, S., Liu, Z.-R., et al. (2016). Specific OCT1 and ABCG2 Polymorphisms Are Associated with Lamotrigine Concentrations in Chinese Patients with Epilepsy. Epilepsy Res. 127, 186–190. doi:10.1016/j.eplepsres.2016.09.004

Shu, Y., Leebman, M. K., Feng, B., Mangravite, L. M., Huang, C. C., Stryke, D., et al. (2003). Evolutionary Conservation Predicts Function of Variants of the Human Organic Cation Transporter, OCT1. Proc. Natl. Acad. Sci. 100, 5902–5907. doi:10.1073/pnas.0730858100

Shu, Y., Sheardown, S. A., Brown, C., Owen, R. P., Zhang, S., Castro, R. A., et al. (2007). Effect of Genetic Variation in the Organic Cation Transporter OCT1 on Metformin Action. J. Clin. Invest. 117, 1422–1431. doi:10.1172/JCI30558

Sturm, A., Gorboulev, V., Gorbunov, D., Keller, T., Volk, C., Schmitt, B. M., et al. (2007). Identification of Cysteines in Rat Organic Cation Transporters rOCT1 (C322, C451) and rOCT2 (C451) Critical for Transport Activity and Substrate Affinity. Am. J. Physiology-Renal Physiol. 293, F767–F779. doi:10.1152/ajprenal.00106.2007

Tzvetkov, M. V., Dos Santos Pereira, J. N., Meineke, I., Saadatmand, A. R., Stijgl, J. C., and Brockmöller, J. (2013). Morphine Is a Substrate of the Organic Cation Transporter OCT1 and Polymorphisms in OCT1 Gene Affect Morphine Pharmacokinetics after Codeine Administration. Biochem. Pharmacol. 86, 666–678. doi:10.1016/j.bcp.2013.06.019

Tzvetkov, M. V., Matthaei, J., Poir, S., Faltraco, F., Vogler, S., Pruop, T., et al. (2018). Increased Systemic Exposure and Stronger Cardiovascular and Metabolic Adverse Reactions to Fenoterol in Individuals with Heritable OCT1 Deficiency. Clin. Pharmacol. Ther. 103, 868–878. doi:10.1002/cpt.812

Tzvetkov, M. V., Saadatmand, A. R., Bokelmann, K., Meineke, I., Kaiser, R., and Brockmöller, J. (2012). Effects of OCT1 Polymorphisms on the Cellular Uptake, Plasma Concentrations and Efficacy of the 5-HT3 Antagonists Tropisetron and Ondansetron. Pharmacogenomics J. 12, 22–29. doi:10.1038/tpj.2010.75

Tzvetkov, M. V., Saadatmand, A. R., Lötsch, J., Tegeder, I., Stijgl, J. C., and Brockmöller, J. (2011). Genetically Polymorphic OCT1: Another Piece in the Puzzle of the Variable Pharmacokinetics and Pharmacodynamics of the Opioidergic Drug Tramadol. Clin. Pharmacol. Ther. 90, 143–150. doi:10.1038/clpt.2011.56

Volk, C., Gorboulev, V., Kotzsch, A., Müller, T. D., and Koepelt, H. (2009). Five Amino Acids in the Innermost Cavity of the Substrate Binding Cleft of Organic Cation Transporter 1 Interact with Extracellular and Intracellular Corticosterone. Mol. Pharmacol. 76, 275–289. doi:10.1124/mol.109.057483

Wang, D. S., Jonker, J. W., Kato, Y., Kusuhara, H., Schinkel, A. H., and Sugiyama, Y. (2002). Involvement of Organic Cation Transporter 1 in Hepatic and Intestinal Distribution of Metformin. J. Pharmacol. Exp. Ther. 302, 510–515. doi:10.1124/jpet.102.034140

Wang, D. S., Kusuhara, H., Kato, Y., Jonker, J. W., Schinkel, A. H., and Sugiyama, Y. (2003). Involvement of Organic Cation Transporter 1 in the Lactic Acidosis Caused by Metformin. Mol. Pharmacol. 63, 844–848. doi:10.1124/mol.63.4.844

Zhou, K., Donnelly, L. A., Kimber, C. H., Donan, P. N., Doney, A. S. F., Leese, G., et al. (2009). Reduced-function SLC22A1 Polymorphisms Encoding Organic Cation Transporter 1 and Glycemic Response to Metformin: a GoDARTS Study. Diabetes 58, 1434–1439. doi:10.2337/db08-0896

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Meyer and Tzvetkov. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.